Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.
about
Concepts and clinical use of ultra-long basal insulinLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesEvaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetesPreventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and CanadaCost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenUtility scores for vesicoureteral reflux and anti-reflux surgery.Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomesApproach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia ToolSevere hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resourcesSelf-rated quality of life of city-dwelling elderly people benefitting from social help: results of a cross-sectional study.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.The patient perspective of diabetes care: a systematic review of stated preference research.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark.History of mild hypoglycaemia does not affect the prevalence of diabetes-related distress in people with diabetes.Individual and societal consequences of hypoglycemia: A cross-sectional survey.Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries.Incidence of non-severe hypoglycaemia and intensity of treatment among veterans with type 2 diabetes in the U.S.A.: a prospective observational study.Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic.Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.
P2860
Q26770354-84CE836B-7DA8-4B64-83F6-5EADB39AD32BQ26784381-2BEFEF19-0B7B-4EF9-9C98-860B6427AB0AQ28069299-F33C665B-A055-42BB-8BBC-1FCC218F8A77Q28554260-FC060EFA-B640-4AAF-822F-AC49FB8BBC4CQ31152059-D2443CF4-E4C3-48C9-9C82-7917868CBB19Q33732593-601D3C92-5D81-44F1-8979-B2BD145A4BE6Q34726534-6A5D4AB9-2EF7-45E3-9B74-1A321BCAD193Q35967501-DCBB4763-F0FC-4726-8FF7-72E82245A1FEQ36860522-CA7159D3-8677-40C2-AD7D-872E5443FF0AQ37269489-91CB6264-9ADA-4F5F-8800-3C0F450BDC95Q37279137-D361CE9E-F347-4CF1-932F-3307C6E2FBF4Q37284658-94F7BDE7-E1CA-4CC0-9465-8E9E9547D9DBQ37639302-6C7511A8-EB63-4B81-ACB4-F8FBBB67EB41Q37689556-6A586E43-5CBD-4000-AEA4-14D87E6D8B7DQ37737461-C8653C8F-C040-4A6D-8A59-961E1759C190Q38201315-DDB8D93D-C4DE-44EC-B263-A80B7EB8B392Q38241834-50FA92FA-E5DC-49DA-A895-0937AB6EDADEQ38470334-B839F7F3-E84E-4D3D-94AD-74A7AC1CE50BQ38675810-66D4C7C5-D480-4594-BD1D-1FBB68801B51Q38738725-04D5D72D-B9A2-4BA2-832E-02C804B9EDFBQ38775589-3EC60152-D823-4B04-9CF3-F54453841DC3Q38907289-DB53565C-9BEE-4284-B82F-3E79E1B499DFQ39321463-AD8ED9AE-BC5E-4CA5-AB2B-97B891AD8678Q39340832-4E2D8FC2-7D13-459E-8CF8-858273D701D7Q39462093-C1C143EA-8782-4D20-8602-D936E1EB96DCQ39667350-C118D4F8-6686-48D8-88D8-F46B602342FFQ39791634-9FE84D2F-8B2D-40C9-AF3A-8499DE011347Q39842123-F8C56688-9664-4C2B-8D73-D7F9F7B500BEQ40649008-4BC0E62E-AC44-42CC-BD28-722753E96683Q41740597-A4838D8B-AA12-4FE5-842E-F0C748EFF96DQ42213808-9B3C4E5B-3D3E-463D-B3BA-9F5D0827CBAFQ44046095-5A7B3100-2CED-4521-80A9-1CB9C839A9FEQ44781339-72583EF7-12DD-46E2-8417-A39C6878B800Q47117737-89CDD8C9-660A-4E0A-A5C5-6218081AD3A9Q47136443-7E62A6AE-0C15-4726-88AD-EDF26A1944CDQ47557627-BF536D64-8CA5-48C8-84BC-CC24FD969185Q48097169-32BBBE6F-36DE-4443-ABA9-411A1AAE0AD1Q50145776-6EFD6348-2618-4C02-BE24-A3B0D75B6FBDQ51241132-942204DE-BE79-4D04-B3BD-B21C58308EF2Q54959259-2C3CBB28-A846-4B7A-A261-1228902F5095
P2860
Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Health-related quality of life ...... -off survey in five countries.
@en
type
label
Health-related quality of life ...... -off survey in five countries.
@en
prefLabel
Health-related quality of life ...... -off survey in five countries.
@en
P2093
P2860
P356
P1476
Health-related quality of life ...... -off survey in five countries.
@en
P2093
Claus B Galbo-Jørgensen
Jens Gundgaard
Marc Evans
Mette Bøgelund
Muhammad Mamdani
Stewart Harris
P2860
P2888
P356
10.1186/1477-7525-11-90
P577
2013-06-03T00:00:00Z
P5875
P6179
1013049175